AUSTIN, Texas, May 17, 2011 /PRNewswire/ -- Rules-Based Medicine (RBM), a global leader in biomarker testing services, today announced the acquisition of intellectual property assets from Satoris, Inc. The portfolio is based on extensive research to discover biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer's disease, frontal temporal dementia, Parkinson's disease, and other conditions that affect the central nervous system.
"These assets from Satoris will be an important contributor as we continue to develop research and diagnostic offerings for neurodegenerative illnesses which affect millions of individuals and families," said Craig Benson, President and CEO of Rules-Based Medicine. "Early detection and intervention will become one of the keys to addressing many of these illnesses. Rules-Based Medicine is committed to the continued investment into areas where an earlier and more precise diagnosis can positively impact the trajectory of these devastating diseases."
Rules-Based Medicine has processed thousands of samples from large patient cohorts assembled to study Alzheimer's disease. Recently published scientific articles or release of biomarker results include studies from Washington University, University of Pennsylvania, the Texas Alzheimer's Research Consortium (TARC) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Using RBM's proprietary testing platform and the DiscoveryMAP(R) collection of over 250 quantitative immunoassays, researchers have recognized the importance of proteomic investigation in achieving a more detailed picture of these complex central nervous system illnesses. RBM will continue to invest in the development of research and clinical biomarker panels that can address the needs of drug developers and physicians for early detection of neurodegenerative disease.
On April 27, 2011, Myriad Genetics of Salt Lake City, a leader in molecular diagnostics, announced an agreement to acquire Rules-Based Medicine. The transaction is expected to be complete by May 31, 2011. RBM headquarters will remain in Austin, TX and will operate as a wholly owned subsidiary of Myriad Genetics under the name Myriad RBM.
About Rules-Based Medicine, Inc.
Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych(TM) is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture(TM), the first fully-closed, reproducible whole blood culture system. More information about RBM is located at http://www.rulesbasedmedicine.com.
SOURCE Rules-Based Medicine, Inc.